PROLONG Study ICD Monitoring Algorithm

Clinical calculation support · Verify results before clinical use

Clinical assessment inputs

Enter the patient's LVEF trajectory and treatment status to review the published PROLONG criteria.

Decision support
The original PROLONG cohort had newly diagnosed LVEF ≤35%.
Optional. If provided, this value is used as the latest LVEF for the current-threshold review.
Optional override. If blank, change is calculated as 3-month LVEF minus baseline LVEF. If an intervening assessment was performed, enter the measured change since that previous visit. Enter percentage-point change, e.g. 5 for 30% to 35%.
Optional clinical context; heart rate is not a stand-alone PROLONG prolongation criterion.
Reset calculator

Clinical context and interpretation

The PROLONG study evaluated patients with newly diagnosed heart failure and LVEF ≤35% who were prescribed a wearable cardioverter-defibrillator while heart-failure therapy was initiated and optimized. At the 3-month reassessment, the investigators proposed considering extension of WCD use when at least one of the following applied:

  • LVEF at the 3-month visit was 30–35% (inclusive).
  • LVEF had increased by at least 5 percentage points compared with the previous assessment.
  • Heart-failure medication was not yet optimized.

Clinical use

These criteria support consideration of continued temporary protection and further reverse-remodelling assessment; they are not a validated score and do not generate an absolute event probability. Decisions about WCD use should be individualized, including adherence, arrhythmic history, competing risks, patient preferences, and local guidance.

ICD eligibility requires a separate guideline-based review. Relevant factors include the underlying disease and etiology, current LVEF, symptoms/NYHA class, duration and optimization of guideline-directed therapy, timing after myocardial infarction or revascularization where applicable, meaningful expected survival, comorbidities, and patient goals. A history of sustained ventricular arrhythmia or cardiac arrest may create a secondary-prevention pathway not covered by this tool.

Input and calculation notes

  • The LVEF increase is expressed in percentage points, not relative percent change.
  • A manually entered change takes precedence. Otherwise, the calculator subtracts baseline LVEF from the 3-month value. If an intervening assessment exists, enter the measured change since that visit manually.
  • The current-threshold review uses the most recent LVEF if entered, otherwise the 3-month LVEF. The 30–35% PROLONG criterion always uses the 3-month value.

References

Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study. J Am Heart Assoc. 2017;6(1):e004512. DOI: 10.1161/JAHA.116.004512. PMID: 28096098.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895–e1032. ICD recommendations require clinical eligibility assessment, including LVEF, symptoms, chronic GDMT, and expected meaningful survival. Official guideline: American Heart Association.
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262.
Clinical disclaimer: This educational decision-support tool reproduces selected PROLONG study criteria and does not replace the original publication, current local guidelines, shared decision-making, or specialist judgement. It does not assess all ICD indications, contraindications, or individual sudden-death risk. Verify measurements and clinical eligibility before making treatment decisions.